Abstract

Grifolin, a natural product isolated from the mushroom Albatrellus confluens, has been reported to be a potent anti-cancer agent in nasopharyngeal carcinoma and osteosarcoma. The data obtained in this study revealed that grifolin is capable of inhibiting the growth and invasion of gastric cancer cells by inducing apoptosis and suppressing the ERK1/2 pathway. Our results support the potent utility of grifolin as an anti-tumor lead compound against gastric cancer cells.

Highlights

  • Gastric cancer (GC) is one of the main causes of cancer-associated mortality, in East Asia, where it has an incidence of approximately 934,000 cases per year [1]

  • It was observed that MEK1 expression was markedly decreased upon treatment with grifolin (Figure 1A), whereas a significant decrease in both MEKK3 and MEK5 expression was observed only in cells treated with a high dose of grifolin (50 μM) (Figure 1B, 1C)

  • Our finding indicated that grifolin might inhibit GC metastasis by modulating the MAPK pathway

Read more

Summary

Introduction

Gastric cancer (GC) is one of the main causes of cancer-associated mortality, in East Asia, where it has an incidence of approximately 934,000 cases per year [1]. The mechanisms of grifolin in tumor cells are not completely understood, grifolin possesses multiple biological activities, including the inhibition of histamine release and NO production [6], antibiotic [7] and anti-oxidant [8] properties and a plasma cholesterol-lowering effect. It was suggested that the death-associated protein kinase 1 (dapk1) gene, which is an apoptosis-related gene, was upregulated at least twofold in response to grifolin treatment in the nasopharyngeal carcinoma cell line CNE1. Grifolin plays an important role in treating nasopharyngeal carcinoma [7] and osteosarcoma [8] by serving as a potent anti-cancer agent. It has not yet been reported whether it possesses an antitumor effect in gastric cancer. We investigated the functions of grifolin in gastric cancer

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call